



PRESS RELEASE

Indoco Q2 revenues at ₹ 3,946 mn

Mumbai, October 24, 2024: During the second quarter of FY 2024-25, revenues of Indoco Remedies are at ₹ 3,946 mn, as against ₹ 4,652 mn, same quarter last year. EBIDTA to net sales for the quarter is 13.4 % at ₹ 529 mn, compared to 15.6% at ₹ 724 mn, same quarter last year. Profit After Tax to net sales is 3.2 % at ₹ 128 mn, compared to 7.1% at ₹ 331 mn, same quarter last year.

Commenting on the results, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “While a good performance by our Domestic Formulation business helped grow revenues, supply constraints have impacted the performance of the International Formulation business. Some of the sites supplying to US and Europe are under structured shutdowns to increase efficiency.”

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 212 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Aloja, Glychek, Kidodent, Subital, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:



Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-4903-9500
Email:
indoco@valoremadvisors.com/corpcor@indoco.com